相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
Jingxian Liu et al.
SCIENTIFIC REPORTS (2019)
The CC′ loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation
Shankar Kundapura et al.
SCIENTIFIC REPORTS (2019)
Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
Mingzhu Wang et al.
COMMUNICATIONS BIOLOGY (2019)
The FG Loop of PD-1 Serves as a Hotspot for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
Danqing Chen et al.
ISCIENCE (2019)
The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions
Tong Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
Zhenkun Na et al.
CELL RESEARCH (2017)
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Shuguang Tan et al.
NATURE COMMUNICATIONS (2017)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Targeting T Cell Co-receptors for Cancer Therapy
Margaret K. Callahan et al.
IMMUNITY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Shoichiro Horita et al.
SCIENTIFIC REPORTS (2016)
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
Yongshu Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
Nivolumab for the treatment of cancer
Anasuya Gunturi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Towards automated crystallographic structure refinement with phenix.refine
Pavel V. Afonine et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
